---
title: "Avalyn Pharma Inc. (AVLN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AVLN.US.md"
symbol: "AVLN.US"
name: "Avalyn Pharma Inc."
datetime: "2026-04-30T18:51:23.809Z"
locales:
  - [en](https://longbridge.com/en/quote/AVLN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AVLN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AVLN.US.md)
---

# Avalyn Pharma Inc. (AVLN.US)

## Company Overview

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis.

| Item | Detail |
|------|--------|
| Exchange | US Market |
| Website | [www.avalynpharma.com](https://www.avalynpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AVLN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AVLN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AVLN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AVLN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**